Advanced Search

Technical Analysis for QTNT - Quotient Limited

Grade Last Price % Change Price Change
grade D 6.42 1.58% 0.10
QTNT closed up 1.58 percent on Thursday, February 27, 2020, on 2.35 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical QTNT trend table...
Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Doji - Bullish? Reversal 1.58%
Lower Bollinger Band Walk Weakness 1.58%
New 52 Week Low Weakness 1.58%
Below Lower BB Weakness 1.58%
Older EOD signals for QTNT ...
View Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
QTNT Chart by TradingView
Basic chart:

Profile

Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania.
Blood Transfusion Medicine Hematology

Is QTNT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Feb 24 Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study
Feb 14 Quotient receives CE mark approval for the Initial Serological Disease Screening Microarray
Feb 14 Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
Feb 4 Quotient Enters Oversold Territory
Feb 4 Edited Transcript of QTNT earnings conference call or presentation 30-Jan-20 1:00pm GMT
Feb 3 Quotient Limited Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Jan 30 Quotient Ltd (QTNT) CEO Franz Walt on Q3 2020 Results - Earnings Call Transcript
Jan 30 Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
Jan 30 Quotient EPS beats by $0.01, beats on revenue
Jan 30 Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results
See more QTNT news...

Indicators

Indicator Value
52 Week High 11.3
52 Week Low 6.02
Average Volume 358,032
200-Day Moving Average 8.78
50-Day Moving Average 8.11
20-Day Moving Average 7.10
10-Day Moving Average 6.85
Average True Range 0.44
ADX 39.85
+DI 8.99
-DI 29.88
Chandelier Exit (Long, 3 ATRs ) 6.96
Chandelier Exit (Short, 3 ATRs ) 7.33
Upper Bollinger Band 7.87
Lower Bollinger Band 6.33
Percent B (%b) 0.06
BandWidth 21.68
MACD Line -0.44
MACD Signal Line -0.40
MACD Histogram -0.044
Fundamentals Value
Market Cap 92.3 Million
Num Shares 14.4 Million
EPS -2.88
Price-to-Earnings (P/E) Ratio -2.23
Price-to-Sales 3.14
Price-to-Book 42.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.43
Resistance 3 (R3) 7.40 7.05 7.26
Resistance 2 (R2) 7.05 6.79 7.06 7.20
Resistance 1 (R1) 6.73 6.63 6.89 6.76 7.15
Pivot Point 6.38 6.38 6.46 6.39 6.38
Support 1 (S1) 6.06 6.12 6.22 6.09 5.69
Support 2 (S2) 5.71 5.96 5.72 5.64
Support 3 (S3) 5.39 5.71 5.58
Support 4 (S4) 5.42